1.Results Among these ED patients who were evaluated,186,71,28,45,21 and 17 cases underwent the above mentioned examinations, and 46 patients were diagnosed as psychological ED,6 as arterial ED,15 as venous ED,3 as hormonal ED,3 as neurologic ED,10 as composite ED and 103 unknown cause ED.
结果 有186、71、2 8、4 5、2 1和 17例患者分别接受了上述检查 ,诊断心理性ED 4 6例 ,动脉性ED 6例 ,静脉性ED 15例 ,内分泌性ED 3例 ,神经性ED 3例 ,混合性ED 10例 ,原因不明 10 3例。
2.Results In 58 patients, there were 30 vasculogenic ED patients including 18 arterial ED, 12 venous ED and 28 non-vasculogenic ED patients.
结果58例患者中确诊血管性ED的患者有30人,其中18名为动脉性ED,12名为静脉性ED,非血管性ED的患者有28人。
3.Results 159 cases of functional ED,206 cases of venous ED,38 cases of arterial ED and 105 cases of mix-type ED were diagnosed.
结果 功能性ED159例,静脉性ED206例,动脉性ED38例,混合性ED105例获得诊断。
4.The PSV(peak systolic velocity),EDV(end diastolic velocity)and RI(resistance index) of helicine arteries in arteriogenic and venogenic ED groups had significant difference with those in the non-vasculariogenic ED group(P<0.05) and the RI of HA in venogenic ED group was lower than that in arteriogenic ED group(P<0.05).
动、静脉性ED组HAs的收缩期峰值流速(PSV)、舒张末期流速(EDV)及阻力指数(RI)与非血管性ED组存在显著差异(P<0.05),静脉性ED组RI明显低于动脉性ED组(P<0.05)。
5.Among 58 patients who were suspicious of vasculogenic ED, 30 patients were diagnosed as having vasculogenic ED (18 arterial ED and 12 venous ED ) and the other 28 were diagnosed as having non-vasculogenic ED.
58例怀疑血管性ED的患者中确诊者有30例,其中18例为动脉性,12例为静脉性,非血管性ED28例。
6.This paper reviewed the efficacy and safety of vardenafil,a highly selective phosphodiesterase type 5(PDE 5) inhibitor,in men with erectile dysfunction who were difficult to treat.Several large-scale studies indicated vardenafil was effective and safe in the treatment of these difficult-to-treat ED patients,including ED with depression or diabetes,ED after radical retropubic prostatectomy,ED caused by spinal cord injury,and sildenafil nonresponders. Vardenafil provides a rational treatment alternative.
本文回顾了高选择性口服磷酸二酯酶5(PDE5)抑制剂伐地那非在各种难治性ED人群的疗效和安全性。 结果表明,伐地那非对于合并糖尿病、抑郁症、前列腺切除术后、外伤性脊髓损伤性、以及西地那非治疗无效的ED患者安全有效,为这些难治性ED人群提供了一种合理的治疗选择。
7.NSB/ T%25 and |r|>0. 9900 in 4 RIA kits when fitting by log dose-logit B/B0 mode,effective dose values-ED25,ED50 and ED75 are in the range of dose-response curves, respectively.
4个RIA药盒的NSB／T％＜5，B0／T＞30，｜r｜＞0．9900，ED（有效剂量值）25、ED50和ED75均在剂量－反应曲线范围内。 每种药盒的质控样品测定均值都落在各自的参考范围内，且批间变异系数均不超过15％。
8.Results There were 22 cases with non-vasculogenic ED (48.9%),12 cases with arteriogenic ED (26.7%) and 11 cases with venogenic ED (24.4%).
结果45例中非血管性ED22例(48.9%),动脉性ED12例(26.7%),静脉性ED11例(24.4%)。
9.ObjectiveTo investigate the changes of angiotensinⅡ(AngⅡ), its receptors (AT1R) and NGF on the diabetic rat model with erectile dysfunction (ED), then using angiotensin receptor blocker (ARB) and exogenous NGF to treat the diabetic rats with ED, so as to evaluate if there is any relationship between them and pathogenesis of diabetic ED.
目的通过观察血管紧张素Ⅱ(AngⅡ)及其受体、神经生长因子(NGF)在雄性糖尿病性勃起功能障碍(DED)大鼠中的变化,初步探讨其在糖尿病性ED发病中的作用,并尝试用AngⅡ受体拮抗剂(ARB)和NGF分别治疗糖尿病性ED,同时观察其对勃起功能障碍的改善情况,从血管和神经两个角度探索糖尿病性ED的发病机制。
10.Results 22 patients had nonvasogenic ED (48.9%),12 patients had ED of arterial origin (26.7%) and 11 patients had ED of venous origin (24.4%).
结果45例中非血管性ED22例(48.9%),动脉性ED12例(26.7%),静脉性ED11例(24.4%)。
